Xeris Pharmaceuticals, Inc.
Chicago, IL Doing business as Xeris
- UEI
- YAV5AK7VKJ31
- CAGE
- 59FN0
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1375 W Fulton St Suite 1300, Chicago, IL 60607, USA
- Website
- xerispharma.com
- Founded
- 2005
- Employees
- 251-1K
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Auto-injectable diazepam formulation for rapid treatment of uncontrolled seizures | National Institute of Neurological Disorders and Stroke | $2,051,241 | |
| Closed-loop glucagon pump for treatment of post-bariatric hypoglycemia | National Institute of Diabetes and Digestive and Kidney Diseases | $1,776,201 | |
| CSI glucagon for treatment of congenital hyperinsulinism | National Institute of Diabetes and Digestive and Kidney Diseases | $1,996,633 | |
| Glucagon mini-dosing pen for treatment of hypoglycemia | National Institutes of Health | $1,130,725 | |
| Clinical development of a stable glucagon formulation for BI-hormonal pump | National Institutes of Health | $1,056,857 |
About Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc., operating as Xeris, is a specialty pharmaceutical company that focuses on developing patient-friendly therapeutic medicines. Xeris is registered in SAM.gov as a corporate entity and small disadvantaged business that manufactures goods. It provides pharmaceuticals and drugs to the federal government through contract vehicles and federal supply schedules.
Xeris holds two relevant Federal Supply Schedule contracts for pharmaceuticals and drugs awarded by the Department of Veterans Affairs (VA). The first is a multiple award schedule under VA Integrated Service Network 12 with a potential value of $4,119,200 from July 2020 to July 2025. This allows the VA to procure Xeris' drugs, pharmaceuticals, and hematology products to support healthcare operations. Against this schedule, the VA National Acquisition Center awarded Xeris a single award Blanket Purchase Agreement (BPA) valued at $661,240.80 for the pharmaceutical KEVEYIS from June 2022 to June 2024. This BPA enables efficient ordering of KEVEYIS, used to treat hyperkalemic periodic paralysis, through established contract terms and pricing. Xeris also holds a separate multiple award Federal Supply Schedule contract awarded in February 2020 by the same VA component, allowing interim procurement of pharmaceuticals valued at $25,000. Through these contract vehicles, Xeris supplies critical drug therapies like KEVEYIS to the VA for treatment of various conditions affecting Veteran patients.
Contract vehicles
Quick answers
What is Xeris Pharmaceuticals, Inc.'s UEI?
Xeris Pharmaceuticals, Inc.'s Unique Entity ID (UEI) in SAM.gov is YAV5AK7VKJ31.
What is Xeris Pharmaceuticals, Inc.'s CAGE code?
Xeris Pharmaceuticals, Inc.'s CAGE code is 59FN0.
What is Xeris Pharmaceuticals, Inc.'s primary NAICS code?
Xeris Pharmaceuticals, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Xeris Pharmaceuticals, Inc. located?
Xeris Pharmaceuticals, Inc.'s physical address in SAM.gov is 1375 W Fulton St Suite 1300, Chicago, IL 60607, USA.
Is Xeris Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Xeris Pharmaceuticals, Inc.'s SAM.gov registration is active through December 18, 2026.
Which contract vehicles does Xeris Pharmaceuticals, Inc. hold?
Xeris Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Xeris Pharmaceuticals, Inc.'s most recent federal award?
Xeris Pharmaceuticals, Inc.'s most recent federal grant award is Auto-injectable diazepam formulation for rapid treatment of uncontrolled seizures (R44NS086229), from National Institute of Neurological Disorders and Stroke, on September 30, 2015.
On GovTribe
See Xeris Pharmaceuticals, Inc.'s full federal record
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors